Most bought healthcare stocks in Q2 2019
See which Healthcare stocks institutional investors increased the most in Q2 2019, measured as net growth in reported share positions from Q1 2019 into Q2 2019. Notable additions at the top of this list include ADAPTIVE BIOTECHNOLOGIES (ADPT), BRIDGEBIO PHARMA INC (BBIO), BRISTOL-MYERS SQUIBB CO (BMY), AVANTOR INC (AVTR). These rankings aggregate SEC 13F filings from all institutional investors in our database.
Explore more:
| Symbol | Name | Net shares | Net value | New | Added | Trimmed | Sold out | Holding now |
|---|---|---|---|---|---|---|---|---|
| ADPT | ADAPTIVE BIOTECHNOLOGIES | 38,406,607 | $1.86B | 1 | 0 | 0 | 0 | 1 |
| BBIO | BRIDGEBIO PHARMA INC | 26,620,991 | $717.97M | 1 | 0 | 0 | 0 | 1 |
| BMY | BRISTOL-MYERS SQUIBB CO | 24,413,120 | $964.10M | 0 | 7 | 2 | 1 | 10 |
| AVTR | AVANTOR INC | 15,733,100 | $300.35M | 2 | 0 | 0 | 0 | 2 |
| CNC | CENTENE CORP | 12,690,620 | $662.32M | 2 | 4 | 0 | 1 | 6 |
| TEVA | TEVA PHARMACEUTICAL-SP ADR | 9,121,270 | -$357.70M | 0 | 3 | 0 | 1 | 6 |
| BSX | BOSTON SCIENTIFIC CORP | 4,326,329 | $235.28M | 0 | 2 | 3 | 1 | 5 |
| BKD | BROOKDALE SENIOR LIVING INC | 4,022,079 | $33.64M | 0 | 1 | 0 | 0 | 1 |
| EXEL | EXELIXIS INC | 3,882,183 | $59.67M | 0 | 1 | 1 | 1 | 2 |
| JNJ | JOHNSON & JOHNSON | 3,503,348 | $477.66M | 0 | 6 | 7 | 1 | 17 |
| TMDX | TRANSMEDICS GROUP INC | 3,499,859 | $87.82M | 1 | 0 | 0 | 0 | 1 |
| ALKS | ALKERMES PLC | 2,299,425 | $28.80M | 0 | 1 | 0 | 1 | 1 |
| ELV | ELEVANCE HEALTH INC | 2,200,975 | $583.28M | 1 | 1 | 4 | 3 | 9 |
| CI | THE CIGNA GROUP | 2,137,234 | $289.07M | 0 | 1 | 3 | 1 | 4 |
| MCRB | SERES THERAPEUTICS INC | 1,892,372 | -$16.50M | 0 | 2 | 0 | 0 | 2 |
| PRGO | Perrigo Company PLC | 1,825,500 | $85.86M | 0 | 2 | 0 | 0 | 3 |
| IONS | IONIS PHARMACEUTICALS INC | 1,719,513 | $107.24M | 1 | 0 | 1 | 1 | 2 |
| NVO | NOVO-NORDISK A/S-SPONS ADR | 1,170,575 | $32.55M | 0 | 2 | 0 | 1 | 2 |
| BIIB | BIOGEN INC | 1,140,974 | $261.10M | 0 | 2 | 2 | 1 | 5 |
| INCY | INCYTE CORP | 1,132,829 | $90.61M | 0 | 2 | 1 | 1 | 4 |
| ARCT | ARCTURUS THERAPEUTICS HOLDIN | 1,004,368 | $9.48M | 1 | 0 | 0 | 0 | 1 |
| ABBV | ABBVIE INC | 958,687 | $31.28M | 0 | 3 | 5 | 1 | 9 |
| COR | CENCORA INC | 802,030 | $96.35M | 0 | 1 | 2 | 1 | 3 |
| UTHR | UNITED THERAPEUTICS CORP | 799,194 | -$25.74M | 0 | 1 | 0 | 1 | 1 |
| CERS | CERUS CORP | 646,902 | -$1.19M | 0 | 1 | 1 | 1 | 2 |
| ARWR | ARROWHEAD PHARMACEUTICALS IN | 618,400 | $17.78M | 0 | 1 | 0 | 0 | 1 |
| OSUR | ORASURE TECHNOLOGIES INC | 610,300 | -$2.48M | 0 | 1 | 0 | 0 | 1 |
| INVA | INNOVIVA INC | 604,320 | $12.21M | 0 | 1 | 0 | 0 | 2 |
| REGN | REGENERON PHARMACEUTICALS | 582,881 | -$12.19M | 0 | 3 | 1 | 1 | 4 |
| PINC | PREMIER INC-CLASS A | 545,324 | $34.71M | 0 | 1 | 0 | 1 | 2 |
| GRFS | GRIFOLS SA-ADR | 541,789 | $23.51M | 0 | 1 | 1 | 1 | 2 |
| CORT | CORCEPT THERAPEUTICS INC | 532,700 | $2.96M | 0 | 1 | 0 | 0 | 1 |
| CTLT | CATALENT INC | 531,335 | $47.84M | 0 | 1 | 1 | 1 | 3 |
| GILD | GILEAD SCIENCES INC | 510,638 | $139.92M | 0 | 3 | 4 | 1 | 8 |
| HQY | HEALTHEQUITY INC | 500,663 | $27.07M | 0 | 1 | 0 | 1 | 1 |
| VRTX | VERTEX PHARMACEUTICALS INC | 456,981 | $80.90M | 0 | 1 | 0 | 1 | 1 |
| CMRX | CHIMERIX INC | 435,380 | $4.82M | 0 | 1 | 0 | 0 | 1 |
| RVNC | REVANCE THERAPEUTICS INC | 428,900 | $3.05M | 0 | 1 | 0 | 0 | 1 |
| NTLA | INTELLIA THERAPEUTICS INC | 426,567 | $1.32M | 1 | 1 | 0 | 0 | 2 |
| VXRT | VAXART INC | 404,883 | -$153.00K | 0 | 1 | 0 | 0 | 1 |
| ENZ | ENZO BIOCHEM INC | 389,419 | $3.35M | 1 | 1 | 0 | 0 | 2 |
| ELAN | ELANCO ANIMAL HEALTH INC | 368,696 | $19.26M | 1 | 1 | 1 | 0 | 3 |
| LAB | STANDARD BIOTOOLS INC | 367,718 | $2.44M | 0 | 1 | 0 | 0 | 1 |
| CLDX | CELLDEX THERAPEUTICS INC | 367,179 | -$237.00K | 0 | 1 | 0 | 0 | 1 |
| LNTH | LANTHEUS HOLDINGS INC | 348,700 | $15.35M | 0 | 1 | 0 | 0 | 1 |
| BDX | BECTON DICKINSON AND CO | 344,793 | $103.14M | 0 | 7 | 0 | 1 | 9 |
| PHG | KONINKLIJKE PHILIPS NVR- NY | 328,333 | $14.71M | 0 | 1 | 0 | 1 | 2 |
| HSIC | HENRY SCHEIN INC | 290,731 | $24.05M | 0 | 1 | 0 | 1 | 1 |
| HBIO | HARVARD BIOSCIENCE INC | 279,500 | -$877.00K | 0 | 1 | 0 | 0 | 1 |
| ACRS | ACLARIS THERAPEUTICS INC | 272,200 | -$1.03M | 0 | 1 | 0 | 0 | 1 |
Frequently asked questions about Most bought healthcare stocks in Q2 2019
What are the most bought Healthcare stocks in Q2 2019?
The most bought healthcare stocks in Q2 2019 are those with the largest increase in reported share counts across institutional investors compared to Q1 2019, based on SEC 13F filings.
Which healthcare stocks did institutional investors added to the most in Q2 2019?
Among filers in this sector, net additions were largest in companies such as ADAPTIVE BIOTECHNOLOGIES (ADPT), BRIDGEBIO PHARMA INC (BBIO), BRISTOL-MYERS SQUIBB CO (BMY), based on aggregated 13F data.
How is institutional buying calculated?
Buying is calculated by summing the net increase in shares reported by institutional investors between two consecutive quarterly 13F snapshots (compared to Q1 2019).
Does this include all institutional owners?
Yes. These rankings aggregate SEC 13F filings from all institutional investors in our database, not only the investors we track individually.
Are these trades real-time?
No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.